The Dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) study demonstrated Farxiga’s potential with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the declining of heart
At present, the mRNA-1893 vaccine is being assessed in a phase 1 study to prevent Zika virus infection in healthy adults. The mRNA-1893 included an mRNA sequence that
Under the terms of the agreement, Siamab will receive a multimillion-dollar initial payment and is eligible to receive additional payments when specific milestones are achieved. No additional terms
Rearranged during transfection (RET) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET fusions are implicated in several cancers including
Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a
The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response
The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic
The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University
The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the
BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock. According to the terms of the Proposal,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.